virus counter reagents rapid, direct, biologically ...the virus counter ® 3100 platform the virus...
Post on 11-Apr-2020
9 Views
Preview:
TRANSCRIPT
Virus Counter® Reagents Rapid, Direct, BiologicallyRelevant Virus Quantification
Infective Particle Empty Particle Defective Particle Unassociated Nucleic Acid Unassociated Protein
Heterogeneity within Virus Samples
Historical Challenges with Virus Quantification
Traditional methods of virus enumeration, including TCID50 or plaque titer assays, quantify infectious particles or units. These methods require considerable time and are burdened with high variability. Other methods for virus quantification, like qPCR and ELISA, quantify a particular component of the virus of interest (nucleic acid or viral protein, respectively) and result in derived titers versus direct quantification.
Quantification of a single virus sample with multiple methods often demontsrates the high degree of variability among methods. This is a result of the inherent heterogeneity of virus samples, which can contain a mixture of infectious particles, empty particles, defective particles, or unassosciated nucleic acid and proteins that derive from unassembled virus and cell components. Different quantification methods may enumerate a subpopu-lation or component within the sample, explaining the disparity among the results.
ELISA assays enumerate the total protein content in the sample and qPCR delivers a readout of total nucleic acid. These techniques can result in a falsely elevated result by the amplification of viral components, rather than intact virus, within the sample. While these methods are generally less time consuming and more reproducible than traditional functional assays, they may fail in effectively relating their readout to total virus counts. In contrast, functional assays quantify the subpopulation of viruses that can successfully infect cells but they cannot be used to investigate non-infectious particles in the sample. These non-infectious particles may be large portion of the total virus popluation, with a potential impact on the safety of virus-derived products and treatments.
The Virus Counter® 3100 Platform
The Virus Counter® 3100 platform is a powerful analytical tool that provides real-time virus counts and can be used throughout virus growth and purification processes. This approach allows differentiation among unassociated proteins and nucleic acid in the sample, as well as discrete particle types, providing a clear advantage of this technology over quantification approaches that only measure one subcomponent of the virus.
The platform enables users to identify optimal harvesting times, validate processing steps, and define final formulations with speed and confidence. The Virus Counter® platform features multiple detection methods, offering the right solution for individual quantification needs.
Speed – Real-time quantification for process monitoring and production optimization
Biologically-relevant readout – Total viral particle quantification
Versatility – High-specificity and universal quantification reagents
Ease of use – software-assisted system operation and data analysis (including 21 CFR Part 11 capabilities)
Reliability – Rugged design for industrial settings, easy system maintenance
The Virus Counter® Platform offers Real-Time Insights into Virus Titers• Assists in optimization of each processing step.
• Allows increased viral vector yield by comparing growth conditions and recovery during process development.
• Enhances protein expression yields and shortened timelines by harvesting with pinpoint precision.
• Provides early identification of problems during manufacturing, minimizing time and cost impacts.
• Increases safety and efficiency by facilitating in-depth characterization of total particle concentration in a final product.
The Virus Counter® instrument detects viral particles in a fluid stream.
Integrated software directs instrument function and enables data analysis.
ViroTag® Assay and Combo Dye® Assay Kits label virus particles using direct, no-wash assays.
Total Particle Quantification Matters
Non-infectious particles can represent a large portion of a virus sample (Figure 1). For this reason, enumerating infectious particle counts alone is not sufficient for in-depth virus sample characterization.
Severe setbacks in early gene therapy clinical trials are illustrative of the importance of total particle quantification. These events induced the FDA to issue new guidelines to minimize the risk of adverse outcomes when using viral vectors: “Given the potential toxicity of the adenoviral particles themselves, CBER recommends that patient dosing be based on particle number” (Guidance for Human Somatic Cell Therapy & Gene Therapy, FDA Centers for Biologics Evaluation and Research, 1998).
In-depth sample characterization of viral vectors is essential to ensure therapy is safe and efficient. This depends not only on the number of infectious particles, but, also on an understanding of potentially adverse side-effects that may be caused by the total viral particles in a dose. Non-infectious particles can represent a large portion of a virus sample, underlining the fact that infectious particle counts alone are not sufficient for thorough virus sample characterization. In the rapidly growing area of viral vector therapy, where the industry struggles to meet demand, optimization of virus manu-facturing is crucial. Rapid and reliable virus quantification allows timely identification of optimal growth conditions and harvesting times, and can increase the productivity of viral vector manufacturing.
Comparison of Infectious Titers with Total Particle Count Samples of Influenza H1N1 (FLU) cytomegalovirus (CMV), respiratory syncytial virus (RSV), and rubella virus (rubella) were measured by 50% tissue culture infective dose assay (TCID50), Virus Counter® platform and quantitative trans-mission electron microscopy (TEM). Total particle counts determined by either TEM or the Virus Counter® platform were statistically undistinguishable. Titer measured by TCID50 was a fraction of total particles, with counts ranging from 2 – 4 orders of magnitude lower than TEM or Virus Counter® platform values.
3
1.00E+05
1.00E+06
1.00E+07
1.00E+09
1.00E+11
1.00E+10
FLU CMV RSV RUBELLA
1.00E+08
ViroCyt Virus Counter TEM TCID50
Difference = NoninfectiveParticles
Tite
r (v
p/m
L)
Virus Counter® platform TEM TCID50
Figure 1: This comparison of infectious titer with total particle counts shows that noninfective particles can be a large portion of the total particle concentration of a virus sample.
30 mins
No Wash AssayBoth Combo Dye® and ViroTag® labeling systems use a rapid, no-wash workflow.
Pipet reagent … … into sample vials con-taining sample with virus within the dynamic range of the instrument.
Mix and incubate protected from light for 30 minutes.
Analyze.
Simple and Quick No-Wash Assay
Utilizing a no-wash assay, virus samples are mixed with Combo Dye® or ViroTag® reagents and incubated for 30 minutes*, protected from light.
* A few ViroTag® reagents might require longer incubation times. Please refer to the Product Information Sheet
Combo Dye® Reagent Virus Sample Sample Analysis Sample Signal
Single Channel SignalUnassociated Nucleic Acid
Single Channel SignalEmpty Particles | Fragments
Simultaneous SignalIntact Virus Particle
Protein Dye
Nucleic Acid Dye
Combo Dye® Reagent: Virus Quantification using a Dual Stain Approach
Combo Dye® reagent is a versatile staining system used in the Virus Counter® platform to rapidly quantify total virus particles. The reagent is based on a dual fluorogenic stain approach: a protein binding dye and a nucleic acid binding dye added simultaneously to virus samples. Upon binding to their respective targets, the quantum yield of the dyes increases significantly. Washing steps to remove unbound dye are unnecessary due to their low, unbound background signal.
Stained samples are guided through the fluidic system of the Virus Counter® instrument where virus bound fluorochromes emit light in response to laser excitation. The emitted light from protein and nucleic acide dyes is measured in two separate channels. Detection of simultaneous signals is interpreted as an intact virus particle. Unassociated nucleic acid or empty capsid are detected as signals in a single channel and are not counted as viruses. The number of events counted during the analysis time is used in combination with sample flow rate to calculate the concentration of virus particles per milliliter of sample.
Laser
+
Versatility of Combo Dye® Reagent
Combo Dye® is suited for enveloped viruses with single- or double-stranded DNA or RNA genomes. Examples of viruses compatible with the Virus Counter® Platform and Combo Dye® reagent:
ArenaviridaePichinde virus
FiloviridaeEbola virusMarburg virus
PoxviridaePox virusVaccinia virus
BaculoviridaeBaculovirus
HerpesviridaeHerpes Simplex Virus ICytomegalovirus
RetroviridaeLentivirusy-Retrovirus
CoronaviridaeCoronavirusInfecious bronchitis virus
OrthomyxoviridaeInfluenza virus
RhabdoviridaeRabies virusVesicular Stomatitis virus
FlaviviridaeDengue virusZika virus
ParamyxoviridaeMeasles virusNewcastle disease virus
TogaviridaeChikungunya
For a complete list please visit: www.sartorius.com/virus-analytics
" We have basically stopped running plaque assays on our P0 and P1 virus stocks because the accuracy of the titers obtained with the Virus Counter® leads to better virus amplifications than those obtained using plaque assay titers. The instrument saves one to two weeks on our virus production time-line and it is very helpful to know within a day or two that a transfection or co-transfection has yielded virus particles."
Kempbio
Titer Determination with High Precision
When analyzing a virus sample for the first time, it is recommended to determine the linear range of the assay (Figure 2) before measuring the titer at an optimal dilution (Figure 3). This protocol ensures measurements in the optimal range of the sample and instrument, and provides high quality data with little variability. Sample titers are determined with high precision and low sample-to-sample (Figure 3) and day-to-day variability (Figure 4).
3
5.5
6.0
6.5
7.0
7.5
8.0
0.51 .0 1.52 .0 2.53 .0 3.5
Log
coun
ts (v
p/m
l)
Log dilution factor
Influenza B/Brisbane
Lentivirus
Baculovirusy = -1.00x + 8.84 R² = 1.00
y = -0.93x + 8.63 R² = 0.99
y = -0.76x + 7.71 R² = 1.00
3
0.00E+00
5.00E+06
1.00E+07
1.50E+07
2.00E+07
2.50E+07
3.00E+07
3.50E+07
4.00E+07
4.50E+07
Influenza B | Brisbane Lentivirus Baculovirus
Aver
age
Tite
r (v
p/m
l)
3
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1 2 3 4
Tite
r (v
p/m
L)
Time (days)
Baculovirus
Figure 2: Determination of linear range of Baculovirus, Influenza virus B/Brisbane and Lentivirus samples using the Virus Counter® Platform.
Figure 3: Optimal dilution within the linear range of the instrument was chosen to determine sample counts in replicates of five. Measured coefficients of variance (CVs) are 10.3% (Influenza B), 10.1% (Lentivirus) and 5.7% (Baculovirus).
Figure 4: Baculovirus titer was determined over a four day period. The measured CV of day-to-day variablity was 6.6%
ViroTag® Reagents: Virus Quantification with Antibody-Based Reagents
Antibody-based ViroTag® reagents are conjugated to fluorophores and bind to their respective targets with high specificity. Viruses that are labeled with ViroTag® reagents are guided through the Virus Counter® instrument and interrogated by a laser, where the conjugated dyes emit light upon excitation. The Virus Counter® instrument detects the emitted light and uses it together with the sample flow rate to calculate total particle concen tration. ViroTag® reagents allow quantification of viruses in crude and purified samples making them the optimal tool to follow virus titer during the whole manufacturing process. ViroTag® reagents are also compatible with VLPs and other particles that do not contain nucleic acids.
Comparison of Quantification Methods Virus titers obtained with ViroTag® reagents using Virus Counter® Platform show a very tight standard deviation compared to many other quantification methods (Figures 5 – 8). Discrepancies among quantification methods are due to the heterogeneity of virus samples. While ELISA and qPCR enumerate total protein or nucleic acid content of a sample, these methods can lead to an overestimation of viral titer due to inclusion of unassociated particles in the quantification process (Figure 5 and 6). Methods such as plaque titer assays and TCID50 quantify only infectious units, while the Virus Counter® platform generates total particle counts (Figure 7 and 8).
3
1.00E+08
1.00E+09
1.00E+10
1.00E+12
1.00E+13
1.00E+11
Aver
age
Tite
r (v
p/m
l)ViroTag® AAV2 – 3 TCID50/ml Transducing
units/mlqPCR
(genomes/ml)ELISA (vp/ml)
5.61E+094.37E+09
5.09E+08
3.28E+10
9.18E+11
3
1.00E+08
1.00E+09
1.00E+10
1.00E+12
1.00E+13
1.00E+11
ViroTag® AAV2/3T CID50/ml Transducingunits/ml
qPCR(genomes/ml)
ELISA (vp/ml)
5.61E+094.37E+09
5.09E+08
3.28E+10
9.18E+11
7.90E+081.49E+09
1.00E+11 6.41E+10
1.00E+00
1.00E+02
1.00E+04
1.00E+06
1.00E+08
1.00E+10
1.00E+12
1.00E+14
Crude Sample Purified Sample
Aver
age
Tite
r (v
p/m
l)
ViroTag® VSV G
ELISA p24
3
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
Aver
age
Tite
r (v
p/m
l)
A/Hon
gKon
g/480
1/201
5
A/Switz
erlan
d/971
5293
A/Texa
s/50/2
012
A/Victo
ria/36
1/201
1
A/Perth
/2009
A/Cali
forn
ia/7/2
009
A/Mich
igan/4
5/201
5
ViroTag® INVA TCID50
3
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
Aver
age
Tite
r (v
p/m
l)
ViroTag® INVB
TCID50
B/Mass
achu
setts/
2/201
2
B/Ph
uket/
3073
/2013
B/Br
isban
e/60/2
008
Figure 5: ViroTag® VSVG reagent was used to quantify to VSV-G pseudotyped Lentivirus samples (crude and purified). CV for Virus Counter® platform measurements were 9 % and 14 %, for p24 ELISA CVs were >50 % for crude and purified sample.
Figure 6: ViroTag® AAV 2/3 was used with other quantification methods to quantify AAV 2 virus standard (ATCC). CV for Virus Counter® platform measurement 2.79 %. CVs measured for other methods from left to right 374 % c.v., 192 % c.v., 109 % c.v., 29.0 % c.v. Data from Lock et al.
Figure 7: Quantification of influenza A strains with ViroTag® INVA reagent and TCID50. ViroTag® result show high precision. ViroTag® reagents quantify total virus particles in the sample compared to TCID50 which enumerates only the infectious subpopulation.
Figure 8: Quantification of influenza B strains with ViroTag® INVB reagent and TCID50. ViroTag® result show high precision and higher quantification results than TCID50. This is due to the quantification of total virus particles with ViroTag® compared to infectious units enumerated with TCID50.
Titer Determination with High Specificity
Which Reagent is Optimal for my Sample?
Enveloped Virus Non-Enveloped Virus
ViroTag® reagent available?
Use Combo Dye® reagent
Use ViroTag® reagent
Particle contains a genome?
ViroTag® reagent available?
Use ViroTag® reagent
Visit website for updates
Crude sample?
Salt concentration over 150 mM?
Serum concentra-tion above 5%?
Sample is compatible with Combo Dye® reagent and ViroTag® reagent
Use ViroTag® reagent
No
No
No
Yes
Yes Yes
No
Ordering Information
Reagent Target Order Number Quantity
AAV2-3 Intact AAV2 and AAV3 capsids VIR-92117 200 samples per kit
BCVB Budded Baculovirus VIR-92108 200 samples per kit
INVA Influenza A Viruses (H1 and H3 subtype) VIR-91151 200 samples per kit
INVB Influenza B Viruses VIR-91152 200 samples per kit
VSVG VSV-G Protein VIR-92332 200 samples per kit
Combo Dye® Universal stain for enveloped viruses VIR-92333 200 samples per kit
Replacement ConsumablesSheath Fluid (Virus Counter® 3100) VIR-92302 1 L bottle
Inter-Sample Wash (ISW) VIR-92303 6 vials
Cleanliness Verification Fluid (CVF) VIR-92295 6 vials
Startup | Shutdown Rinse (SSR) VIR-92338 6 vials
Yes
3
1.00E+08
1.00E+09
1.00E+10
1.00E+12
1.00E+13
1.00E+11
Aver
age
Tite
r (v
p/m
l)
ViroTag® AAV2 – 3 TCID50/ml Transducingunits/ml
qPCR(genomes/ml)
ELISA (vp/ml)
5.61E+094.37E+09
5.09E+08
3.28E+10
9.18E+11
Sales and Service ContactsFor further contacts, visit www.sartorius-stedim.com
EuropeGermanySartorius Stedim Biotech GmbHAugust-Spindler-Strasse 1137079 Goettingen
Phone +49.551.308.0
Sartorius Stedim Systems GmbHRobert-Bosch-Strasse 5 – 7 34302 Guxhagen
Phone +49.5665.407.0
FranceSartorius Stedim FMT S.A.S.ZI des PaludsAvenue de Jouques – CS 9105113781 Aubagne Cedex
Phone +33.442.845600
Sartorius Stedim France SASZI des PaludsAvenue de Jouques – CS 7105813781 Aubagne Cedex
Phone +33.442.845600
AustriaSartorius Stedim Austria GmbHModecenterstrasse 221030 Vienna
Phone +43.1.7965763.18
BelgiumSartorius Stedim Belgium N.V.Rue Colonel Bourg 1051030 Bruxelles
Phone +32.2.756.06.80
HungarySartorius Stedim Hungária Kft.Kagyló u. 52092 Budakeszi
Phone +36.23.457.227
ItalySartorius Stedim Italy S.r.l.Via dell’Antella, 76/A50012 Antella-Bagno a Ripoli (FI)
Phone +39.055.63.40.41
NetherlandsSartorius Stedim Netherlands B.V.
Phone +31.30.60.25.080
filtratie.nederland@sartorius-stedim.com
PolandSartorius Stedim Poland Sp. z o.o.ul. Wrzesinska 7062-025 Kostrzyn
Phone +48.61.647.38.40
Russian FederationLLC “Sartorius Stedim RUS”Vasilyevsky Island5th line 70, Lit. A199178 St. Petersburg
Phone +7.812.327.53.27
SpainSartorius Stedim Spain, S.A.U.Avda. de la Industria, 32Edificio PAYMA28108 Alcobendas (Madrid)
Phone +34.913.586.098
SwitzerlandSartorius Stedim Switzerland AGRingstrasse 24 a8317 Tagelswangen
Phone +41.52.354.36.36
U.K.Sartorius Stedim UK Ltd.Longmead Business CentreBlenheim Road, EpsomSurrey KT19 9 QQ
Phone +44.1372.737159
UkraineLLC “Sartorius Stedim RUS”Post Box 440 “B”01001 Kiev, Ukraine
Phone +380.44.411.4918
AmericasUSASartorius Stedim North America Inc.5 Orville Drive, Suite 200Bohemia, NY 11716
Toll-Free +1.800.368.7178
ArgentinaSartorius Argentina S.A. Int. A. Ávalos 4251 B1605ECS Munro Buenos Aires
Phone +54.11.4721.0505
BrazilSartorius do Brasil Ltda Avenida Senador Vergueiro 2962 São Bernardo do Campo CEP 09600-000 - SP- Brasil
Phone +55.11.4362.8900
MexicoSartorius de México, S.A. de C.V.Libramiento Norte de Tepotzotlan s/n,Colonia Barrio Tlacateco,Municipio de Tepotzotlan,Estado de México,C.P. 54605
Phone +52.55.5562.1102
leadsmex@sartorius.com
Asia|PacificAustraliaSartorius Stedim Australia Pty. Ltd.Unit 5, 7-11 Rodeo DriveDandenong South Vic 3175
Phone +61.3.8762.1800
ChinaSartorius Stedim (Shanghai) Trading Co., Ltd.3rd Floor, North Wing, Tower 1No. 4560 Jinke RoadZhangjiang Hi-Tech Park Pudong DistrictShanghai 201210, P.R. China
Phone +86.21.6878.2300
Sartorius Stedim (Shanghai) Trading Co., Ltd.Beijing Branch OfficeNo. 33 Yu’an RoadAirport Industrial Park Zone BShunyi District, Beijing 101300
Phone +86.10.8042.6501
Sartorius Stedim (Shanghai) Trading Co., Ltd. Guangzhou Branch OfficeRoom 1105Xing Guang Ying Jing BuildingNo. 119, Shui Yin Road Yue Xiu District, Guangzhou 510075
Phone +86.20.3836.4193
IndiaSartorius Stedim India Pvt. Ltd.#69/2-69/3, NH 48, JakkasandraNelamangala Tq562 123 Bangalore, India
Phone +91.80.4350.5250
JapanSartorius Stedim Japan K.K.4th Fl., Daiwa Shinagawa North Bldg.8-11, Kita-Shinagawa 1-chomeShinagawa-ku, Tokyo, 140-0001 Japan
Phone +81.3.4331.4300
MalaysiaSartorius Stedim Malaysia Sdn. Bhd.Lot L3-E-3B, Enterprise 4Technology Park MalaysiaBukit Jalil57000 Kuala Lumpur, Malaysia
Phone +60.3.8996.0622
SingaporeSartorius Stedim Singapore Pte. Ltd.10 Science Park Rd The Alpha #02-13/14Singapore Science Park IISingapore 117684
Phone +65.6872.3966
South KoreaSartorius Korea Biotech Co., Ltd.8th Floor, Solid Space B/D, PanGyoYeok-Ro 220, BunDang-GuSeongNam-Si, GyeongGi-Do, 463-400
Phone +82.31.622.5700
www.sartorius-stedim.com Spec
ific
atio
ns s
ubje
ct t
o ch
ange
wit
hout
not
ice.
Cop
yrig
ht S
arto
rius
Sted
im B
iote
ch G
mbH
. Prin
ted
in t
he E
U o
n pa
per b
leac
hed
wit
hout
chl
orin
e.
Vers
ion
1 / 2
019
/ 03
Learn why leaders in vaccine development, protein expression, and viral therapeutics choose the Virus Counter® 3100 Platform as their tool of choice for virus quantitation. Please visit: www.sartorius.com/virus-analytics
www.sartorius.com/virus-analytics
The Virus Counter® Platform is for research use or further manufacturing use only – not for use in thera-peutic or diagnostic procedures. They are not for in vitro diagnostic use nor are they medical devices. Drug manufacturers and clinicians are responsible for obtaining the appropriate IND/BLA/NDA approvals for clinical applications.
Sartorius Stedim Biotech GmbHAugust-Spindler-Strasse 1137079 Goettingen, GermanyPhone +49.551.308.0www.sartorius-stedim.com
USA Toll-Free +1.800.368.7178Argentina +54.11.4721.0505Brazil +55.11.4362.8900Mexico +52.55.5562.1102UK +44.1372.737159France +33.442.845600Italy +39.055.63.40.41Spain +34.913.586.098Russian Federation +7.812.327.53.27Japan +81.3.4331.4300China +86.21.6878.2300
Specifications subject to change without notice. Printed and copyrighted by Sartorius Stedim Biotech GmbH. | WPublication No.: Order No.: Ver. 01 | 2012
Selected References
• Evaluation of the Virus Counter® for Rapid Baculovirus Quantitation. Journal of Virological Methods, 2011, 171(1); Ferris et al.
• Evaluation of ViroCyt® Virus Counter® for Rapid Filovirus Quantitation. Viruses, 2015, 7; pp 857-872; Rossi et al.
• Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes. Virology, 2016, 499, pp 322-330; Lülf et al.
• Rapid and Effective Monitoring of Baculovirus Concentrations in Bioprocess Fluid Using the ViroCyt® Virus Counter®. BioProcessing Journal, 2014, 13(2), pp32-39; Birch et al.
• Characterization of Human Influenza Viruses Propagated by Madin-Darby Canine Kidney Cells or Embryonated Eggs. International Journal of Virology and AIDS 2014; Plant et al.
• Virotherapy Process Optimization. Bioprocessing Journal, 2015, 14(1); Artinger et al.
• Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale. Human Gene Therapy (2010); Lock, M. et al.
top related